Who We Are
Novoxel® was founded in 2011 with the mission to transform fractional skin rejuvenation through treatments that are innovative for both the clinician and patients. Our close partnership with the medical community, including leading physicians on our advisory panel, drives us toward this vision.
Our TMA® technology stands out as a patient-friendly, green, and versatile solution for fractional skin resurfacing, backed by safety demonstrated in clinical studies. Presently, our patented products and technology are available in over 50 countries around the world. We are committed to reshaping the medicine by continuously developing novel solutions and maintaining excellence in all aspects of our work.
Novoxel Ltd. , known for its innovative technology, dedicates significant resources to R&D and Intellectual Property (IP) protection. IP protection is vital to Novoxel's mission of enhancing aesthetic dermatologic treatments for patients and doctors. We implement a robust global IP strategy and the products featured on our website are protected by patents and/or designs, with additional IP protections issued or pending.
Innovation you can depend on.
Quality Management
Novoxel is committed to Quality
We are certified and operate under a Quality Management system which complies with ISO 13485:2016 for design, manufacture and customer support.
We are certified and regulated under the Medical Device Regulation, EU Quality Management System Certificate - MDR 725869
Our family of products comply with additional local regulations in the countries where they are marketed.
Trademarks
Our trademarks are becoming well-recognized around the world.
The following trademarks are registered by Novoxel Ltd.:
Novoxel
Tixel
Tixel C
Tixel 2
Thermo-Mechanical Action
TMA
MezoTix
Tixel i
Tixel Eye
Patents & Designs
We continue to innovate and have been granted over 65 patents around the world.
The following are the patents and designs for the USA:
US 9,402,678 B2
US 10,327,832 B2
US 10,702,328 B2
US 11,083,515 B2
US 11,291,498 B2
US 11,439,455 B2
D903132 S
D903133 S
Global Presence
Founded in 2011, Novoxel has expanded to new serve the worldwide demand:
Manufacturing/Operations HQ:
Netanya, Israel
Europe HQ
2014: Novoxel GmbH
Berlin, Germany
Asia/Pacific HQ
2022: Novoxel KK
Tokyo, Japan
USA HQ:
2024: Novoxel Inc.
Knoxville, Tennessee
Our Advisors
Our Advisory Board includes an impressive collection of world-renowned
dermatologists, plastic surgeons, ophthalmologists, optometrists and other physicians,
including: Ofir Artzi, Christine Dierickx, Steven Weiner, Gregg Berdy, and April Jasper.
Our Products
The Future
of Skin Technology
Leveraging our exclusive Thermo-Mechanical Action technology
(TMA®), Tixel® seamlessly integrates heat and motion.
Utilizing a medical-grade, in situ sterile titanium tip, it delicately administers pure natural heat to the skin, ensuring safe progression towards noticeable outcomes. Tixel accommodates all skin types and an extensive range of aesthetic and medical procedures, supported by patented non-invasive technology
and validated clinical outcomes featured in numerous peer-reviewed publications.
Versatile, user-friendly, and ergonomically designed, Tixel® proves ideal for clinics of varying sizes and multi-site practices alike.
tixel
Handpieces
The large tip consists of a 9x9 array of tiny pyramids, while the small tip is a 4x6 array. The heated pyramids are blunt and do not pierce the skin.
When the trigger is activated, the tip moves forward to make brief contact with the skin. This creates a matrix of discrete, hemispherical coagulation zones. The resulting biochemical activity stimulates cytokines, neocollagenesis, and a cascade of rejuvenating effects.
Tixel C transfers pure heat to the skin quickly and safely by very brief contact. The thermal effect induces renewal of epidermal cells and regeneration of collagen in the dermis.
The compact device is perfect for clinicians who travel between academic centers and their clinics.
Contact Us
What questions can we answer for you?
